EC 359
Alternative Names: EC-359; LIF antagonistLatest Information Update: 22 Jun 2024
Price :
$50 *
At a glance
- Originator Evestra
- Class Antineoplastics; Small molecules
- Mechanism of Action Leukaemia inhibitory factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Breast cancer; Ovarian cancer; Pancreatic cancer
- No development reported Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Ovarian Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Ovarian Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)